Items where Author is "Mirzania, M."
 | Up a level |
Group by: Item Type | No Grouping
Number of items: 2.
(2022) Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial. BMC Cancer. p. 10.
(2015) Medical Oncology, History and Its Future in Iran. Archives of Iranian Medicine. pp. 799-805. ISSN 1029-2977